Navidea Biopharmaceuticals (NAVB) - NYSEMKT
  • Nov. 20, 2014, 8:29 AM
    • The European Commission clears Navidea Biopharmaceuticals' (NYSEMKT:NAVB) Lymphoseek (technetium Tc 99m tilmanocept) for use in imaging and intraoperative detection of sentinel lymph nodes draining a primary tumor in adult patients with breast cancer, melanoma or localized squamous cell carcinoma of the oral cavity.
    • The company plans to launch the product in certain major markets in 2015.
    | Nov. 20, 2014, 8:29 AM | 4 Comments
  • Nov. 11, 2014, 7:55 AM
    • The FDA refunds Navidea Biopharmaceuticals' (NYSEMKT:NAVB) $1.1M PDUFA filing fee for Lymphoseek (technetium Tc 99m tilmanocept) pursuant to its granting of Orphan Drug status for its use in sentinel lymph node detection in patients with head and neck cancer.
    • Separately, the company's major investor, Platinum Partners, reaffirmed its $31.8M line of credit.
    | Nov. 11, 2014, 7:55 AM | 3 Comments
  • Nov. 10, 2014, 12:59 PM
    | Nov. 10, 2014, 12:59 PM | 1 Comment
  • Nov. 6, 2014, 7:34 AM
    • Navidea Biopharm (NYSEMKT:NAVB): Q3 EPS of -$0.05 beats by $0.01.
    • Revenue of $2.25M (+462.5% Y/Y) beats by $0.71M.
    | Nov. 6, 2014, 7:34 AM | 8 Comments
  • Nov. 5, 2014, 5:30 PM
  • Oct. 15, 2014, 9:18 AM
    • Navidea Biopharmaceuticals (NYSEMKT:NAVB) appoints Rick Gonzalez CEO effective October 13. He joins the firm from Spectrum Pharmaceuticals where he was VP of Global Operations.
    | Oct. 15, 2014, 9:18 AM
  • Oct. 15, 2014, 7:30 AM
    • The FDA approves Navidea Biopharmaceuticals' (NYSEMKT:NAVB) Lymphoseek (technetium Tc 99m tilmanocept) sNDA for its expanded use in mapping solid tumors and adding Sentinel Lymph Node detection for breast cancer and melanoma to its approved indications.
    • Lymphoseek is now approved for lymphatic mapping using a handheld gamma counter to locate lymph nodes draining a primary tumor site in patients with solid tumors for which this procedure is a component of intraoperative management and guiding Sentinel Lymph Node Biopsy using a handheld gamma counter in patients with clinically node negative squamous cell carcinoma of the oral cavity, breast cancer or melanoma.
    • The FDA also allowed the expanded utilization of Lymphoseek with or without scintigraphic imaging (lymphoscintigraphy) to enable preoperative imaging and mapping of lymph nodes to facilitate node localization during surgical procedures.
    • Lymphoseek is the only FDA-approved agent for lymphatic mapping across solid tumors when used as a component of surgical management.
    • NAVB is up 2% premarket on 5,500 shares.
    | Oct. 15, 2014, 7:30 AM
  • Oct. 8, 2014, 11:16 AM
    • October 16 is the PDUFA date for the FDA's review of Navidea Biopharmaceuticals' (NAVB) sNDA for an expanded label for Lymphoseek (technetium 99m tilmanocept) Injection. The applied-for label supports broader and more flexible use in imaging and lymphatic mapping procedures, including lymphoscintigraphy imaging and flexible timing of Lymphoseek administration allowing for a two-day protocol.
    | Oct. 8, 2014, 11:16 AM | 14 Comments
  • Sep. 26, 2014, 10:00 AM
    • The EMA's Committee for Medicinal Products for Human Use (CHMP) adopts a positive opinion supporting marketing approval for Navidea Biopharmaceuticals' (NAVB +5.6%) Lymphoseek 250 mcg kit for radiopharmaceutical preparation (tilmanocept). The recommended indication is for use in imaging and intraoperative detection of sentinel lymph nodes draining a primary tumor in adult patients with breast cancer, melanoma or head and neck oral cavity squamous cell carcinoma.
    • A final decision by the European Commission generally takes ~60 days.
    • The FDA approved a label expansion for Lymphoseek in June to include squamous cell carcinoma in the head and neck region.
    | Sep. 26, 2014, 10:00 AM | 7 Comments
  • Sep. 26, 2014, 9:14 AM
    | Sep. 26, 2014, 9:14 AM
  • Sep. 23, 2014, 8:18 AM
    • The National Cancer Institute awards a Fast Track Small Business Innovation Research grant of up to $1.67M to Navidea Biopharmaceuticals (NYSEMKT:NAVB) to fund the evaluation of Lymphoseek (technetium Tc 99m tilmanocept) Injection in women with cervical cancer.
    • The grant will be awarded in two parts over a 2.5-year span. The first tranche of $165,917 has already been awarded. It will fund the company's activities in identifying and qualifying clinical trial sites and securing the requisite contracts and IRB approvals. The remaining $1.5M will fund the actual trial and data analysis.
    • The study is expected to involve 40 patients and last 1.5 years.
    | Sep. 23, 2014, 8:18 AM | 3 Comments
  • Sep. 19, 2014, 9:24 AM
    | Sep. 19, 2014, 9:24 AM
  • Sep. 18, 2014, 5:16 PM
    • The FDA designates Navidea Biopharmaceuticals' (NAVB +14%) Lymphoseek (technetium Tc 99m tilmanocept) an Orphan Drug for use in sentinel lymph node detection in patients with cancer of the head and neck.
    • Orphan Drug status provides for a seven-year period of exclusivity, SPA assistance, tax credits and qualifies the company to request a refund of previously-paid filing fees up to $1.1M.
    | Sep. 18, 2014, 5:16 PM | 3 Comments
  • Sep. 4, 2014, 8:36 AM
    • Navidea Biopharmaceuticals (NYSEMKT:NAVB) enters into an exclusive agreement with a wholly-owned subsidiary of Hainan Sinotau Pharmaceutical Co., Ltd., to develop and commercialize Lymphoseek (technetium Tc 99m tilmanocept) Injection in China.
    • Under the terms of the agreement, Navidea will earn royalties on units sales, an upfront payment of $300K, up to $700K in development milestone payments and up to $1.5M in sales-related milestones.
    • Sinotau is responsible for funding and conducting clinical studies and regulatory submissions to the China Food and Drug Administration. It will be responsible for all sales and marketing activities post approval in China exclusive of Hong Kong, Macau and Taiwan.
    | Sep. 4, 2014, 8:36 AM | 2 Comments
  • Aug. 11, 2014, 8:19 PM
    • Navidea Biopharmaceuticals (NAVB -1.5%) Q2 results: $1.1M (+450.3%); Operating Loss: ($9.2M) (-9.0%); Net Loss: ($10.2M) (+1.0%): Loss Per Share: ($0.07) (+22.2%); Quick Assets: $17.5M (-46.8%).
    • No financial guidance given.
    | Aug. 11, 2014, 8:19 PM | 1 Comment
  • Aug. 6, 2014, 9:30 AM
    • Navidea Biopharmaceuticals (NYSEMKT:NAVB) Q2 results: Total Revenues: $1.1M (+450.3%); Gross Profit: $804.2K (+795.5%); Operating Expenses: $10.0M (+17.6%); Operating Loss: ($9.2M) (-9.0%); Net Loss: ($10.2M) (+1.0%); Loss Per Share: ($0.07) (+22.2%); Quick Assets: $17.5M (-46.8%).
    • No guidance given.
    | Aug. 6, 2014, 9:30 AM
Company Description
Navidea Biopharmaceuticals, Inc. develops and commercializes precision diagnostics and radiopharmaceutical agents, which are intended to improve diagnostic accuracy, clinical decision-making and patient care. Its current radiopharmaceutical development programs include Lymphoseek, AZD4694 and... More
Sector: Healthcare
Industry: Medical Appliances & Equipment
Country: United States